In a report on recent drug recalls, one risk analyst suggests they don't. Aggressive cost-cutting in both in manufacturing operations and in the supply chain may be contributing to the quality problems that have led to a wave of product recalls in the dru

Protecting the public’s health shouldn’t fall to the whistleblowers, an editorial in yesterday's Boston Globe says, pointing to a $750 million GlaxoSmithKline settlement late last month in which a whistleblower claimed the company had knowingly sold unsaf

What happened... By now, no one needs a detailed recap of the election itself. Although Senate Democrats may have done a little better than expected, the U.S. House of Representatives made a major swing to the right, as did statehouses across the country.

Drugmaker Genentech's new promotion to get eye doctors to use the expensive injectable drug Lucentis for macular degeneration offers rebates to top-prescribing practices based on bulk and rate of increased use, the New York Times reports, despite little e

Citizens in three states cast their votes on anti-Affordable Care Act (ACA) ballot initiatives on Tuesday. All of the ballot measures presented citizens with an up or down vote on whether the state constitution should be amended to allow its citizens to l

A new survey of pharmaceutical executives found that even as they expect to send a larger share of drug manufacturing, sourcing and sales to emerging economies such as China, India, and Brazil, many are not confident in the willingness or ability of their

Today's Pharmalot had a great interview with Jon Liebowitz, the Chairman of the FTC, on the problem of pay-for-delay settlements that prevent consumer access to generic versions of Provigil, Androgel, and Cipro. With  more and more consumers telling PAL a

Community Catalyst’s “Insider” is much in demand this week, traveling from one end of the country to the other to provide policy insights on children’s health (at the New England Children’s Health Summit in New Hampshire) and health reform implementation

Drugmaker GlaxoSmithKline settled for $750 million in federal court yesterday over charges this that it knowingly sold unsafe drugs that didn’t meet quality standards set by the company and the FDA. The drugs include Paxil CR, an antidepressant, Bactroban